[Novo Nordisk shareholders say the company needs to expand its business through acquisitions] On September 20, it was reported that Novo Nordisk shareholders urged the pharmaceutical group to expand its product portfolio through acquisitions to reduce its profit dependence on the diabetes treatment drug Ozempic. Eugen Uretzki, an analyst at company shareholder Flossbach, said the development potential of Novo Nordisk's assets "still has to be proven." Julia Angeles, investment manager at Novo Nordisk investor Baillie Gifford, said the pharmaceutical company needs to explain how it will transition away from reliance on Ozempic; possible options include seeking partnerships to explore more experimental treatments. Angeles said investors need to see the company's plans in terms of deals.